Abstract:Objective To investigate the clinical effect of dapagliflozin combined with intensive insulin therapy on refractory type 2 diabetes mellitus (T2DM). Methods A total of 90 patients with refractory T2DM who received treatment from July 2017 to July 2019 were selected and divided into control group (intensive insulin therapy) and experimental group (dapagliflozin + intensive insulin therapy) randomly (n=45, each).All the patients were treated for 12 weeks.Insulin dosage, blood glucose level, C-peptide level, HOMA-IR, BMI, blood lipid, blood pressure, serum uric acid (SUA) level and adverse reactions were compared between the two groups before and after treatment. Results There was no significant difference in baseline indexes between the two groups before treatment (P>0.05).After treatment, insulin dosage, fasting blood glucose (FPG), 2-hour postprandial blood glucose (2hPBG), glycosylated hemoglobin (HbA1c), C-peptide, HOMA-IR, BMI, triglyceride (TG), serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), SUA levels in the experimental group were lower than those in the control group (P<0.05), and high-density lipoprotein cholesterol (HDL-C) was higher than that in control group (P<0.05).There was no significant difference in adverse reactions between the two groups (P>0.05). Conclusion Dapagliflozin combined with intensive insulin therapy of refractory T2DM can reduce blood glucose, blood uric acid levels and insulin resistance significantly, and it can regulate blood lipids.